Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$7.70 and last traded at C$7.60, with a volume of 47408 shares trading hands. The stock had previously closed at C$7.55.

Knight Therapeutics Stock Performance

The firm has a fifty day moving average price of C$6.61 and a 200 day moving average price of C$6.18. The company has a current ratio of 2.39, a quick ratio of 1.79 and a debt-to-equity ratio of 10.15. The firm has a market cap of C$743.26 million, a PE ratio of -151.60, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.29.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings data on Thursday, March 19th. The company reported C$0.09 earnings per share (EPS) for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The firm had revenue of C$133.20 million during the quarter. As a group, equities research analysts expect that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.